<DOC>
	<DOC>NCT02401373</DOC>
	<brief_summary>This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between 18-60 years in China.</brief_summary>
	<brief_title>A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.</brief_title>
	<detailed_description>This is a single center, open, dose-escalation clinical trial. According to the Chinese guidelines for vaccine clinical trial, the sample size of a phase 1 clinical trial should be at least 20. In this study, a total of 60 participants will be included.30 participants will be firstly recruited and assigned to receive the low dose Ad5-EBOV. After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose Ad5-EBOV. The whole follow-up period for each participant will be 28 days.</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged between 18 and 60 years. African in China. Able to understand the content of informed consent and willing to sign the informed consent Able and willing to complete all the secluded study process during the whole study followup period (about 1 month). A body mass index (BMI) 18.535.0 kg/m2 Hemoglobin ≥110g/L for female, and ≥120g/L for male. White blood cells (WBC) 4.010.0×109 cells/L Total lymphocyte Count 0.84.5×109 cells/L Platelets 100300×109 cells/L Alanine aminotransferase (ALT) 040U/L Serum creatinine 44106μmol/L Active partial thromboplastin time (APTT) 2040 seconds Prothrombin time (PT) 1014 seconds Negative in HIV diagnostic blood test Axillary temperature ≤37.0°C on the day of enrollment General good health as established by medical history and physical examination. Family history of seizure, epilepsy, brain or mental disease Participant that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5EBOV, such as mannitol. Woman who is pregnant, breastfeeding or positive in βHCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months Any acute fever disease or infections in last 7 days Major congenital defects or not wellcontrolled chronic illness, such as asthma, diabetes, or thyroid disease Hereditary angioneurotic edema or acquired angioneurotic edema Urticaria in last one year Asplenia or functional asplenia Platelet disorder or other bleeding disorder may cause injection contraindication Faint at the sight of blood or needles. Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months Prior administration of blood products in last 4 months Prior administration of other research medicines in last 1 month Prior administration of attenuated vaccine in last 1 month Prior administration of inactivated vaccine in last 14 days Current antituberculosis prophylaxis or therapy Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Vaccines</keyword>
	<keyword>Ebola Virus Disease</keyword>
</DOC>